The stock of Telesis Bio Inc (TBIO) has gone down by -58.22% for the week, with a -54.82% drop in the past month and a -63.64% drop in the past quarter. The volatility ratio for the week is 13.50%, and the volatility levels for the past 30 days are 9.09% for TBIO. The simple moving average for the past 20 days is -53.07% for TBIO’s stock, with a -72.20% simple moving average for the past 200 days.
Is It Worth Investing in Telesis Bio Inc (NASDAQ: TBIO) Right Now?
Moreover, the 36-month beta value for TBIO is 1.80. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TBIO is 0.52M and currently, short sellers hold a 2.36% of that float. On September 16, 2024, TBIO’s average trading volume was 135.44K shares.
TBIO) stock’s latest price update
Telesis Bio Inc (NASDAQ: TBIO) has experienced a decline in its stock price by -11.60 compared to its previous closing price of 1.81. However, the company has seen a fall of -58.22% in its stock price over the last five trading days. globenewswire.com reported 2024-09-10 that SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) — Telesis Bio Inc. (NASDAQ: TBIO) (“Telesis” or the “Company”), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, announced today that it has notified the Nasdaq Stock Market LLC (“Nasdaq”) of its decision to delist the Company’s shares of common stock, par value $0.001 per share (the “Common Stock”) and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
TBIO Trading at -57.22% from the 50-Day Moving Average
After a stumble in the market that brought TBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.46% of loss for the given period.
Volatility was left at 9.09%, however, over the last 30 days, the volatility rate increased by 13.50%, as shares sank -55.80% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -57.67% lower at present.
During the last 5 trading sessions, TBIO fell by -58.22%, which changed the moving average for the period of 200-days by -74.11% in comparison to the 20-day moving average, which settled at $3.3080. In addition, Telesis Bio Inc saw -77.72% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TBIO
Current profitability levels for the company are sitting at:
- -2.01 for the present operating margin
- 0.33 for the gross margin
The net margin for Telesis Bio Inc stands at -2.83. The total capital return value is set at -0.79. Equity return is now at value -146.98, with -58.02 for asset returns.
Based on Telesis Bio Inc (TBIO), the company’s capital structure generated 0.42 points at debt to capital in total, while cash flow to debt ratio is standing at -3.08. The debt to equity ratio resting at 0.71. The interest coverage ratio of the stock is -11.92.
Currently, EBITDA for the company is -31.05 million with net debt to EBITDA at -0.93. When we switch over and look at the enterprise to sales, we see a ratio of 1.82. The receivables turnover for the company is 13.14for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.89.
Conclusion
To wrap up, the performance of Telesis Bio Inc (TBIO) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
